0001179110-18-006013.txt : 20180501
0001179110-18-006013.hdr.sgml : 20180501
20180501182856
ACCESSION NUMBER: 0001179110-18-006013
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20180427
FILED AS OF DATE: 20180501
DATE AS OF CHANGE: 20180501
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: MARINO JAMES J
CENTRAL INDEX KEY: 0001198578
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36020
FILM NUMBER: 18796915
MAIL ADDRESS:
STREET 1: C/O ONCONOVA THERAPEUTICS
STREET 2: 375 PHEASANT RUN
CITY: NEWTOWN
STATE: PA
ZIP: 18940
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Onconova Therapeutics, Inc.
CENTRAL INDEX KEY: 0001130598
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 375 PHEASANT RUN
CITY: NEWTOWN
STATE: PA
ZIP: 18940
BUSINESS PHONE: 267-759-3681
MAIL ADDRESS:
STREET 1: 375 PHEASANT RUN
CITY: NEWTOWN
STATE: PA
ZIP: 18940
FORMER COMPANY:
FORMER CONFORMED NAME: ONCONOVA THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20090526
FORMER COMPANY:
FORMER CONFORMED NAME: ONCONOVA THERAPEUTICS INC
DATE OF NAME CHANGE: 20001226
4
1
edgar.xml
FORM 4 -
X0306
4
2018-04-27
0
0001130598
Onconova Therapeutics, Inc.
ONTX
0001198578
MARINO JAMES J
C/O ONCONOVA THERAPEUTICS
375 PHEASANT RUN
NEWTOWN
PA
18940
1
0
0
0
Common Stock
2018-04-27
4
P
0
58900
A
145221
D
Warrant (right to purchase)
.425
2018-04-27
4
P
0
58900
0
A
2018-04-27
Series B Convertible Prefered Stock
1472.50
58900
D
The common stock and warrants reported on this Form 4 were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425. The public offering, during which the Company also sold other securities, was pursuant to the Company's effective registration statement on Form S-1 (File No. 333-224315).
The warrants are exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and will expire on the 18-month anniversary of the date on which the Company publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware.
/s/ Mark Guerin as attorney-in-fact
2018-05-01